RecOVARY? Using anti-Müllerian hormone to predict ovarian function after anti-HER2 therapy for early breast cancer

Lynn K Symonds^{1

2}, Nancy E Davidson^{1

2}

Affiliations

¹ Fred Hutchinson Cancer Center, Seattle, WA, United States.
² Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States.

Comment

Lynn K Symonds et al. J Natl Cancer Inst. 2025.

. 2025 Nov 1;117(11):2158-2160.

doi: 10.1093/jnci/djaf247.

Lynn K Symonds^{1

2}, Nancy E Davidson^{1

2}

¹ Fred Hutchinson Cancer Center, Seattle, WA, United States.
² Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States.

No abstract available

Comment on

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.
Lambertini M, Allegranza D, Laubender RP, Harbeck N, Swain SM, Geyer CE, Slamon DJ, Bobba G, Lambertini C, de Haas S, Restuccia E, Vaz-Luis I, Cameron DA, Krop IE, Winer EP, Anderson RA. Lambertini M, et al. J Natl Cancer Inst. 2025 Nov 1;117(11):2317-2326. doi: 10.1093/jnci/djaf198. J Natl Cancer Inst. 2025. PMID: 40796347 Free PMC article. Clinical Trial.